Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...